FindTrial
Sign In

NVX-CoV2373

BIOLOGICAL6 trials

Sponsors

Masaryk University, Novavax, Cogna Technology Solutions LLC

Conditions

Adverse Reaction to VaccineCOVID-19COVID19 VaccineSARS CoV 2 InfectionSARS-CoV-2 InfectionSevere Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Phase 2

A Study to Evaluate Safety and Immunogenicity of a COVID-19 Vaccine in People Living With HIV at Risk for SARS-CoV-2 (COVID-19)
CompletedNCT05112848
NovavaxSARS-CoV-2 Infection
Start: 2022-02-28End: 2022-11-30Updated: 2023-03-16

Phase 3

Phase 3 Boosting Study for the SARS-CoV-2 rS Vaccine
CompletedNCT05249816
Cogna Technology Solutions LLCSevere Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Start: 2022-03-18End: 2023-05-04Updated: 2023-08-02
Phase 3 Boosting Study for the SARS-CoV-2 rS Variant Vaccines
CompletedNCT05372588
NovavaxCOVID-19, SARS CoV 2 Infection
Start: 2022-05-25End: 2024-04-07Updated: 2024-04-23
Study to Compare the Immunogenicity and Safety of 3 Lots of NVX-CoV2373 in Adults
CompletedNCT05463068
NovavaxCOVID-19, SARS-CoV-2 Infection
Start: 2022-07-11End: 2022-09-01Updated: 2026-04-17
Phase 3 Study of Novavax Vaccine(s) as Booster Dose After mRNA Vaccines
CompletedNCT05875701
NovavaxCOVID-19
Start: 2023-03-28End: 2023-11-11Updated: 2025-06-26

Unknown Phase

COVID-19 Vaccines Safety Tracking (CoVaST)
RecruitingNCT04834869
Masaryk UniversityAdverse Reaction to Vaccine, COVID19 Vaccine
Start: 2021-04-01End: 2026-12-31Target: 30000Updated: 2022-04-06

Related Papers

Immunogenicity of adjuvanted recombinant SARS-CoV-2 spike protein vaccine after earlier mRNA vaccine doses.
2025-03-26
P-1972. SARS-CoV-2 Vaccine–Induced IgG4 Response Negatively Correlates with Neutralizing Antibodies and Fc Effector Functions
Open Forum Infectious Diseases2025-01-29
Immunogenicity and safety of SARS-CoV-2 recombinant spike protein vaccine in South African people living with and without HIV-1 infection: A phase 2 randomised trial.
2024-09-271 citations
Immunogenicity and Safety of Heterologous Omicron BA.1 and Bivalent SARS-CoV-2 Recombinant Spike Protein Booster Vaccines: A Phase 3 Randomized Clinical Trial.
2024-07-016 citations
Immunogenicity and safety of a bivalent (omicron BA.5 plus ancestral) SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose: interim analysis of a phase 3, non-inferiority, randomised, clinical trial.
2024-03-0615 citations
2337. Immunogenicity and Safety of a Heterologous Booster Dose of Omicron Subvariant (BA.1 and BA.5) and Bivalent SARS-CoV-2 Recombinant Spike Protein Vaccines: A Phase 3, Randomized, Clinical Trial
Open Forum Infectious Diseases2023-11-271 citations
Immunogenicity and safety of NVX-CoV2373 as a booster: A phase 3 randomized clinical trial in adults.
2023-08-307 citations
COVID-19 Vaccines Safety Tracking (CoVaST): Protocol of a Multi-Center Prospective Cohort Study for Active Surveillance of COVID-19 Vaccines’ Side Effects
International Journal of Environmental Research and Public Health2021-07-2568 citations
International COVID-19 Vaccines Safety Tracking Study (CoVaST-RU): Participation of the Russian Federation
Russian Journal of Preventive Medicine2021-01-011 citations